Sage Therapeutics and Biogen have decided to abandon efforts to gain approval for Zurzuvae in the broader major depressive disorder market, focusing instead on postpartum depression after the FDA limited its use. The companies are prioritizing resources due to the significant investment required for further studies, leading to a 40% workforce reduction at Sage. Despite setbacks, executives remain optimistic about Zurzuvae's performance in postpartum depression, noting encouraging prescription trends and insurance coverage.
AbbVie has agreed to acquire Aliada Therapeutics for $1.4 billion, gaining access to innovative drug delivery technology aimed at overcoming the blood-brain barrier and a clinical-stage Alzheimer’s treatment, ALIA-1758. This move aligns with AbbVie’s focus on neuroscience, enhancing its capabilities in developing therapies for neurological disorders. The deal is expected to close by year-end and reflects a strategic investment in a sector facing challenges but also potential breakthroughs.
Sage Therapeutics' experimental drug dalzanemdor (SAGE-718) has failed in a mid-stage trial for Alzheimer’s, showing no significant cognitive improvement over placebo. Following this setback, the company will not pursue further development for Alzheimer’s and faces low expectations for upcoming Huntington’s disease trials. Sage's stock has dropped significantly this year, reflecting ongoing challenges after previous drug failures and a major workforce reduction.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
